{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T20:07:40Z","timestamp":1769717260418,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10067-025-07796-z","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T22:28:33Z","timestamp":1763072913000},"page":"73-79","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost optimizing tocilizumab therapy in stable rheumatoid arthritis: a dose de-escalation nomogram to prevent overuse and unnecessary costs"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8131-796X","authenticated-orcid":false,"given":"Kaja","family":"van Soest","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9087","authenticated-orcid":false,"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirian J. F.","family":"Starmans-Kool","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7655-6094","authenticated-orcid":false,"given":"Nieko C.","family":"Punt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0577-6620","authenticated-orcid":false,"given":"Robert B. M.","family":"Landew\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4236-2726","authenticated-orcid":false,"given":"Niels W.","family":"Boone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"7796_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-540-73259-4_7","volume":"181","author":"N Nishimoto","year":"2018","unstructured":"Nishimoto N, Kishimoto T (2018) Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol 181:151\u2013160","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"7796_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"key":"7796_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/03009742.2016.1183039","volume":"46","author":"EL Kneepkens","year":"2017","unstructured":"Kneepkens EL, Van den Oever IAM et al (2017) Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study. Scand J Rheumatol 46:87\u201394. https:\/\/doi.org\/10.1080\/03009742.2016.1183039","journal-title":"Scand J Rheumatol"},{"key":"7796_CR4","unstructured":"European Medicines Agency. Summary of Product Characteristics Roactemra (2013). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/roactemra-epar-product-information_en.pdf (Accessed 3 March 2025)."},{"key":"7796_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40744-018-0102-x","volume":"5","author":"A Rubbert-Roth","year":"2018","unstructured":"Rubbert-Roth A, Furst DE et al (2018) A review of recent advances using tocilizumab in the treatment of rheumatic diseases. Rheumatol Ther 5:49\u201368. https:\/\/doi.org\/10.1007\/s40744-018-0102-x","journal-title":"Rheumatol Ther"},{"key":"7796_CR6","unstructured":"European Medicines Agency (2010) Scientific discussion for RoActemra. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion-variation\/roactemra-h-c-955-ii-0007-epar-scientific-discussion-variation_en.pdf (Accessed 3 March 2025)."},{"key":"7796_CR7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1177\/0091270009350623","volume":"50","author":"N Frey","year":"2010","unstructured":"Frey N, Grange S, Woodworth T (2010) Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol 50:754\u2013766. https:\/\/doi.org\/10.1177\/0091270009350623","journal-title":"J Clin Pharmacol"},{"key":"7796_CR8","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/bcp.15690","volume":"91","author":"NW Boone","year":"2025","unstructured":"Boone NW, Moes DJAR, Ramiro S et al (2025) Single dose tocilizumab for COVID-19 associated cytokine storm syndrome: less is more. Br J Clin Pharmacol 91:938\u2013946. https:\/\/doi.org\/10.1111\/bcp.15690","journal-title":"Br J Clin Pharmacol"},{"key":"7796_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2022-222155","volume":"82","author":"CLM Krieckaert","year":"2023","unstructured":"Krieckaert CLM, Van Tubergen A, Gehin JE et al (2023) EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 82:65\u201373. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222155","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"7796_CR10","doi-asserted-by":"publisher","first-page":"e00216","DOI":"10.1136\/rmdopen-2022-002216","volume":"8","author":"C Krieckaert","year":"2022","unstructured":"Krieckaert C, Hern\u00e1ndez-Breijo GJE et al (2022) Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. RMD Open 8(2):e00216. https:\/\/doi.org\/10.1136\/rmdopen-2022-002216","journal-title":"RMD Open"},{"key":"7796_CR11","doi-asserted-by":"publisher","unstructured":"Benucci M, Meacci F, Grossi V et al (2016) Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab. Biologics: Targets Ther 10:53\u201358. https:\/\/doi.org\/10.2147\/BTT.S97234","DOI":"10.2147\/BTT.S97234"},{"key":"7796_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/0091270012437585","volume":"53","author":"M Levi","year":"2013","unstructured":"Levi M, Grange S, Frey N (2013) Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis. J Clin Pharmacol 53:151\u2013159. https:\/\/doi.org\/10.1177\/0091270012437585","journal-title":"J Clin Pharmacol"},{"key":"7796_CR13","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1111\/bcp.13954","volume":"85","author":"C Bastida","year":"2019","unstructured":"Bastida C, Soy D, Ruiz-Esquide V et al (2019) Exposure-response modelling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components. Br J Clin Pharmacol 85:1710\u20131718. https:\/\/doi.org\/10.1111\/bcp.13954","journal-title":"Br J Clin Pharmacol"},{"key":"7796_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00228-020-02925-w","volume":"76","author":"C Bastida","year":"2020","unstructured":"Bastida C, Huitema ADR, L\u2019Ami MJ et al (2020) Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic\/pharmacodynamic simulations. Eur J Clin Pharmacol 76:123\u2013135. https:\/\/doi.org\/10.1007\/s00228-020-02925-w","journal-title":"Eur J Clin Pharmacol"},{"key":"7796_CR15","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ et al (2010) 2010 rheumatoid arthritis classification criteria: an ACR\/EULAR collaborative initiative. Ann Rheum Dis 69:1580\u20131588. https:\/\/doi.org\/10.1136\/ard.2010.138461","journal-title":"Ann Rheum Dis"},{"key":"7796_CR16","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"key":"7796_CR17","unstructured":"Sanquin: tocilizumab (2024). https:\/\/www.sanquin.org\/products-and-services\/bioanalysis-of-biologics\/available-kits-and-services\/tocilizumab\/index (Accessed 3 March 2025)."},{"key":"7796_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.4103\/1735-5362.301335","volume":"15","author":"DR Brocks","year":"2020","unstructured":"Brocks DR, Hamdy H (2020) Bayesian estimation of pharmacokinetic parameters: an important component to include in the teaching of clinical pharmacokinetics and therapeutic drug monitoring. Res Pharm Sci 15:503\u2013514. https:\/\/doi.org\/10.4103\/1735-5362.301335","journal-title":"Res Pharm Sci"},{"key":"7796_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0304851","volume":"19","author":"HH Chen","year":"2024","unstructured":"Chen HH, Yemeke T, Ozawa S (2024) Reduction of biologic pricing following biosimilar introduction: analysis across 57 countries and regions. PLoS ONE 19:e0304851. https:\/\/doi.org\/10.1371\/journal.pone.0304851","journal-title":"PLoS ONE"},{"key":"7796_CR20","unstructured":"Farmacotherapeutisch Kompas (2025): kosten tocilizumab. https:\/\/www.farmacotherapeutischkompas.nl\/bladeren\/preparaatteksten\/t\/tocilizumab#kosten (Accessed 3 March 2025)."},{"key":"7796_CR21","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1136\/annrheumdis-2016-209201","volume":"75","author":"G Schett","year":"2016","unstructured":"Schett G, Emery P, Tanaka Y et al (2016) Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis 75:1428\u20131437. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209201","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07796-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07796-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07796-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T09:42:15Z","timestamp":1769679735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07796-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7796"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07796-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All patients provided written consent for participation in this study and received feedback on the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}